|
Match
|
Document |
Document Title |
|
|
7202048 |
Onset of force development as a marker of thrombin generation
Platelet contractile force (PCF) is used as a surrogate marker of thrombin generation. PCF generation occurs concomitant with the burst of prothrombin fragment F 1+2 release. The time between assay...
|
|
|
RE39548 |
Interleukin-5 specific recombinant antibodies
An effective anti-IL-5 recombinant antibody molecule comprising heavy and/or light chain antigen-binding residues from a donor antibody.
|
|
|
7198919 |
Use of alpha factor sequences in yeast expression systems
The isolation of the yeast α-factor genes is described. The promoter and signal peptide portions are isolated and joined to DNA coding for proteins heterologous to yeast in a plasmid which is used...
|
|
|
7196175 |
Antibodies to JTT-1 protein and cells secreting such antibodies
Novel cell surface molecules recognized by monoclonal antibodies against a cell surface molecule of lymphocytic cells that play an important role in autoimmune diseases and allergic diseases have...
|
|
|
7192714 |
LDL receptor signaling assays
The invention provides methods and compositions for modeling and detecting LDL receptor transmembrane signaling by detecting proteolysis of an LDL receptor transmembrane domain. The method...
|
|
|
7189397 |
Cytotoxicity mediation of cells evidencing surface expression of CD44
This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease...
|
|
|
7189820 |
Antibodies against tumor necrosis factor delta (APRIL)
The present invention relates to antibodies and related molecules that immunospecifically bind to Tumor Necrosis Factor Delta (TNF-delta; APRIL). The present invention also relates to methods and...
|
|
|
7189825 |
Cancerous disease modifying antibodies
The present invention relates to a method for producing patient cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer...
|
|
|
7189824 |
Tumor vessel endothelial cell-binding monoclonal antibodies
A monoclonal antibody which recognizes an antigen of a molecular weight of 40 kD or 80 kD on the surface of tumor vessel endothelial cells, hybridomas producing the monoclonal antibody,...
|
|
|
7186529 |
Preparation of erythropoietin by endogenous gene activation
The invention relates to human cells which are capable, on the basis of an activation of the endogenous human EPO gene, of producing EPO in a sufficient amount and purity to make possible a...
|
|
|
7186820 |
Production of humanised antibodies to TNFα
There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human TNFα. There is also disclosed a CDR grafted antibody wherein...
|
|
|
7183388 |
Anti-MUC-1 single chain antibodies for tumor targeting
This invention provides novel antibodies that specifically bind to the cancer antigen MUC-1. The antibodies are useful targeting moieties for specifically directing imaging agents and various...
|
|
|
7183108 |
Selection and uses of lactic acid bacteria strains modulating non-specific immunity
The invention concerns lactic acid bacteria strains capable of regulating the production of NO and inflammatory cytokines by enterocytes, depending on the inflammatory condition of said...
|
|
|
7179595 |
Compositions and methods for generating antigen-binding units
The present invention provides non-single-chain antigen-binding units that is stabilized by leucine zipper sequences. The experimental design is particularly useful for generating and screening for...
|
|
|
7175996 |
Methods of optimizing antibody variable region binding affinity
The present invention relates to compositions and methods of producing higher affinity molecules, and in particular, higher affinity antibodies. Specifically, the invention contemplates methods of...
|
|
|
7173000 |
Modified factor VIIa
A modified factor VIIa is provided. The modified factor has increased amidolytic activity in the absence of T.F. and a higher affinity for T.F. when compared to the native factor VIIa but does not...
|
|
|
7169908 |
Purification of polypeptides
A method for purifying a desired heterologous polypeptide from microbial fermentation broth or homogenate in which it is produced and solubilized is described. This method involves adding to the...
|
|
|
7166577 |
Albumin having enhanced antimicrobial activity
The present invention provides a nitrosylated albumin variant wherein one or more amino acid residues of constituent amino acid sequences are substituted, or a different amino acid residue is...
|
|
|
7163817 |
Clot-specific streptokinase proteins possessing altered plasminogen activation characteristics and a process for their preparation
The invention disclosed herein provides clot specific streptokinase proteins possessing altered plasminogen characteristics, including enhanced fibrin selectivity. The kinetics of plasminogen...
|
|
|
7151164 |
Anti-CD20 antibodies and fusion proteins thereof and methods of use
The present invention provides humanized, chimeric and human anti-CD20 antibodies and CD 20 antibody fusion proteins that bind to a human B cell marker, referred to as CD20, which is useful for the...
|
|
|
7132511 |
Modified anti-EGFR antibodies with reduced immunogenicity
The present invention relates to antibodies which are directed to the EGF receptor (HER1) to be administered especially to humans and in particular for therapeutic use in tumors. The antibodies are...
|
|
|
7132510 |
Specific human antibodies for selective cancer therapy
The present invention is directed to novel peptides and polypeptides that specifically bind to target cells and may have anti-cancer activity, especially blood-related cancers. The present...
|
|
|
7132281 |
Methods and host cells for producing human monoclonal antibodies to CTLA-4
In accordance with the present invention, there are provided fully human monoclonal antibodies against human cytotoxic T-lymphocyte antigen 4 (CTLA-4). Nucelotide sequences encoding and amino acid...
|
|
|
7122646 |
Multivalent and multispecific binding proteins, their manufacture and use
Polypeptides comprising a first domain, which comprises a binding region of an immunoglobulin heavy chain variable region, and a second domain, which comprises a binding region of an immunoglobulin...
|
|
|
7122634 |
Modified factor VIII
Specific amino acid loci of human factor VIII interact with inhibitory antibodies of hemophilia patients who have developed such antibodies after being treated with factor VIII. Modified factor...
|
|
|
7122185 |
Anti-CCR5 antibody
The invention is directed an anti-CCR5 antibody which comprises (i) two light chains, each light chain comprising the expression product of a plasmid designated pVK:HuPRO140-VK (ATCC Deposit...
|
|
|
7118889 |
Protein tyrosine kinase substrate LAT and its use in the indentification of (ant)agonists of the kinase
The invention generally relates to compositions and methods for identifying and testing tyrosine kinase signaling pathway agonists and antagonists, and more particularly, methods and compositions...
|
|
|
7112420 |
Lymphoma associated molecules and uses therefor
The invention provides isolated nucleic acids molecules, designated BBAP nucleic acid molecules, which encode proteins that interact with or bind to BAL molecules, which are differentially...
|
|
|
7105330 |
Human plasma hyaluronidase
The invention is based on the discovery of methods for purification of an acid active hyaluronidase found in human plasma (hpHAse), including both biochemical and immunoaffinity purification...
|
|
|
RE39270 |
Process for continuous optimized protein production in insect larvae
The present invention provides for a recombinant insect larvae and a process of manufacturing proteins utilizing insect larvae that allows for the selection of individual larvae for harvest at the...
|
|
|
7098006 |
Chimeric antibody, pharmaceutical composition and process of its production
An altered antibody chain is produced in which the CDR's of the variable domain of the chain are derived from a first mammalian species. The framework-encoding regions of DNA encoding the variable...
|
|
|
7098383 |
Methods for the production of multimeric immunoglobulins, and related compositions
Improved methods for the production of multimeric-protein-complexes, such as redox proteins and immunoglobulins, in association with oil bodies are described. The redox protein is enzymatically...
|
|
|
7094574 |
Recombinant cell clones having increased stability and methods of making and using the same
Disclosed are a stable recombinant cell clones which are stable in serum- and protein-free medium for at least 40 generations, a biomass obtained by multiplying the stable cell clone under serum-...
|
|
|
7090844 |
Use of antibodies against the MUC18 antigen
The present invention relates generally to the generation and characterization of anti-MUC18 monoclonal antibodies. The invention further relates to the use of such anti-MUC18 antibodies in the...
|
|
|
7087409 |
Humanization of murine antibody
A humanized murine antibody is provided. The amino acid sequences of a light chain complementarity determining region from a mouse antibody are grafted onto a human light chain, and a heavy chain...
|
|
|
7087405 |
Nucleic acids encoding anti-human ανβ3 and ανβ5 antibodies
This invention relates to novel humanized and other recombinant or engineered antibodies or monoclonal antibodies to a human α v subunit-containing heterodimeric integrin receptors and to the...
|
|
|
7081518 |
Anti-mesothelin antibodies having high binding affinity
Mesothelin is a differentiation antigen present on the surface of ovarian cancers, mesotheliomas and several other types of human cancers. Because among normal tissues, mesothelin is only present...
|
|
|
7070989 |
Escherichia coli strain secreting human granulocyte colony stimulating factor (G-CSF)
The present invention provides a recombinant plasmid vector comprising a kanamycin resistance gene, a promoter, an endoxylanase signal sequence, a nucleotide sequence coding for an oligopeptide...
|
|
|
7067131 |
Methods for using anti-MUC18 antibodies
The present invention relates generally to the generation and characterization of anti-MUC18 monoclonal antibodies. The invention further relates to the use of such anti-MUC18 antibodies in the...
|
|
|
7067284 |
Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
The present invention describes methods for producing antibody libraries, and particularly for increasing antibody library diversity by inducing mutagenesis within the CDR regions of immunoglobulin...
|
|
|
7060453 |
Method and kit for the determination of analyte concentration in blood
A method is provided for determining the level of an analyte in the blood of an individual based on determination of the level of the same analyte in non-blood sample (e.g. urine, saliva and hair)...
|
|
|
7060808 |
Humanized anti-EGF receptor monoclonal antibody
A nucleic acid is provided which encodes a humanized antibody or fragment thereof, which encodes a protein which binds to human EGF-receptor. Monoclonal antibody 225 is the complementary...
|
|
|
7052872 |
Bi-specific antibodies for pre-targeting diagnosis and therapy
The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that specifically binds a targeted tissue and at least one other arm that specifically binds a...
|
|
|
7052873 |
Natural human antibody
A reshaped human anti-HM1.24 antibody comprising:
(A) L chains each comprising (1) a constant region of a human L chain, and (2) FRs of a human L chain, and CDRs of L chain of mouse...
|
|
|
7049099 |
Recombinant human mannan-binding proteins and producing method of the same
Recombinant Human Mannan-Binding Proteins (rhMBP) having physiological activities which are substantially identical to those offered by Human Mannan-Binding Proteins (hMBP), as well as, in...
|
|
|
7033798 |
Method for the stabilization of chimeric immunoglobulins or immunoglobulin fragments, and stabilized anti-EGP-2 scFv fragment
The present invention relates to a method for stabilizing chimeric immunoglobulins or immunoglobulin fragments. Furthermore, the invention also provides a stabilized anti-EGP-2 scFv fragment.
|
|
|
7029876 |
Process for production of polypeptides
Vectors for producing polypeptides heterologous to prokaryotes are described comprising, along with the polypeptide-encoding nucleic acid, anti-termination nucleic acid that inhibits intragenic...
|
|
|
7022500 |
Humanized immunoglobulins
Novel methods for producing, and compositions of, humanized immunoglobulins having one or more complementarity determining regions (CDR's) and possible additional amino acids from a donor...
|
|
|
7005511 |
Fluorescent protein variants and methods for making same
The present invention relates generally to variant fluorescent proteins, and more specifically to monomeric and dimeric forms of Anthozoan fluorescent proteins. In one aspect, the present invention...
|
|
|
6998253 |
Altered polypeptides with increased half-life
Polypeptides that are cleared from the kidney and do not contain in their original form a Fc region of an IgG are altered so as to comprise a salvage receptor binding epitope of an Fc region of an...
|